Business
Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates
REDWOOD CITY, Calif. & BOSTON, May 06, 2025--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the first quarter ended March 31, 2025.
About this update from Adicet Bio, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":288,"url":"https://media.zenfs.com/en/business-wire.com/eaafb45739b32daaf2ee6cfd68aa034b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AtCcCVZ69_W6pbchPa0Geg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU3NjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/eaafb45739b32daaf2ee6cfd68aa034b","width":480,"height":288}},"lazy":false},{"type":"text","content":"Two programs with clinical data readouts in 2H/2025","length":51,"tagName":"p","attribs":{}},{"type":"text","content":"Phase 1 clinical trial of ADI-001 in autoimmune diseases ongoing with preliminary clinical data expected in 2H/2025; Trial now open for enrollment to patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE)","length":223,"tagName":"p","attribs":{}},{"type":"text","content":"Preliminary data for ongoing ADI-270 Phase 1 clinical trial in patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC) expected in 2H/2025","length":156,"tagName":"p","attribs":{}},{"type":"text","content":"REDWOOD CITY, Calif. & BOSTON, May 06, 2025--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the first quarter ended March 31, 2025.","length":344,"tagName":"p"},{"type":"text","content":""We are approaching an exciting inflection point for our pipeline, with significant data milestones on the horizon," said Chen Schor, President and Chief Executive Officer of Adicet Bio. "In the second half of 2025, we expect to report preliminary Phase 1 data from our two lead programs - ADI-001 in autoimmune diseases and ADI-270 in ccRCC, with more than 6 patients with at least 3-month follow up in both programs. As we progress toward these readouts, we also look to harness the full potential of our allogeneic gamma delta 1 CAR T cell therapy platform, which we believe has key advantages over other cell types. We have identified two promising highly differentiated programs, one targeting PSMA and one follow-on program targeting autoimmune diseases with potential to become best-in-class therapies for ...